Security Snapshot

SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) Institutional Ownership

CUSIP: 78397T202

13F Institutional Holders and Ownership History from Q4 2023 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

48

Shares (Excl. Options)

36,342,111

Price

$3.74

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
SABS on Nasdaq
Shares outstanding
73,850,758
Price per share
$4.59
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
36,342,111
Total reported value
$135,919,535
% of total 13F portfolios
0%
Share change
+6,119,671
Value change
+$25,718,819
Number of holders
48
Price from insider filings
$4.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 78397T202.
  • 48 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 34 to 48 between Q3 2025 and Q4 2025.
  • Reported value moved from $56,328,113 to $135,919,535.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 78397T202?
CUSIP 78397T202 identifies SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vivo Opportunity Fund Holdings, L.P. 10% $54,973,720 25,931,000 Vivo Opportunity Fund Holdings, L.P. 29 Sep 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $30,195,359 +$8,858,028 7,311,225 +42% RA Capital Management, L.P. 19 Mar 2026
Woodline Partners LP 9.9% $14,323,021 7,125,881 Woodline Partners LP 30 Sep 2025
BIOTECHNOLOGY VALUE FUND L P 9.1% -8.9% $18,761,910 -$1,598,505 4,761,906 -7.9% BVF PARTNERS L P/IL 31 Dec 2025
Commodore Capital LP 9.9% $9,588,711 4,522,977 Commodore Capital LP 26 Sep 2025
PERCEPTIVE ADVISORS LLC 7.3% $13,088,916 3,471,861 Perceptive Advisors LLC 14 Jan 2026
RTW INVESTMENTS, LP 3.2% -68% $6,253,970 +$2,218,090 1,587,302 +55% RTW Investments, LP 31 Dec 2025

As of 31 Dec 2025, 48 institutional investors reported holding 36,342,111 shares of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS). This represents 49% of the company’s total 73,850,758 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Vivo Capital, LLC 15% 11,420,000 0% 2.8% $42,710,800
Commodore Capital LP 6% 4,401,500 0% 1.1% $16,461,610
RA CAPITAL MANAGEMENT, L.P. 6% 4,401,500 0% 0.17% $16,461,610
Woodline Partners LP 3.9% 2,850,881 0% 0.04% $10,662,295
Spruce Street Capital LP 3% 2,198,502 0% 2.7% $8,222,397
Sessa Capital IM, L.P. 3% 2,198,457 0% 0.16% $8,222,229
Blackstone Inc. 2.9% 2,143,585 0.04% $8,017,008
VANGUARD GROUP INC 2.5% 1,847,136 +405% 0% $6,908,288
PERCEPTIVE ADVISORS LLC 1.1% 803,210 0.06% $3,004,005
Propel Bio Management, LLC 0.88% 652,881 2.1% $2,441,775
Jefferies Financial Group Inc. 0.79% 580,328 0.02% $2,170,427
Balyasny Asset Management L.P. 0.64% 475,439 0% $1,778,142
MILLENNIUM MANAGEMENT LLC 0.44% 324,090 0% $1,212,097
HB Wealth Management, LLC 0.42% 307,500 0% 0.01% $1,150,050
AMERIPRISE FINANCIAL INC 0.38% 283,645 0% $1,060,833
MARSHALL WACE, LLP 0.32% 236,460 0% $884,360
Simplify Asset Management Inc. 0.28% 208,227 0.01% $778,769
AWM Investment Company, Inc. 0.27% 200,000 0% 0.07% $748,000
STEMPOINT CAPITAL LP 0.2% 146,558 0.09% $548,127
GEODE CAPITAL MANAGEMENT, LLC 0.16% 119,517 +39% 0% $447,037
ExodusPoint Capital Management, LP 0.12% 86,113 0% $322,063
GOLDMAN SACHS GROUP INC 0.07% 51,348 +358% 0% $192,042
Pathstone Holdings, LLC 0.07% 50,650 0% 0% $189,433
OMERS ADMINISTRATION Corp 0.06% 42,000 0% $157,080
Qube Research & Technologies Ltd 0.04% 31,147 0% $116,490

Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 36,342,111 $135,919,535 +$25,718,819 $3.74 48
2025 Q3 28,023,938 $56,328,113 +$52,469,483 $2.01 34
2025 Q2 1,923,874 $3,369,565 -$378,633 $1.76 25
2025 Q1 2,209,552 $2,994,479 -$1,776,863 $1.36 26
2024 Q4 2,652,300 $10,189,778 -$1,266,185 $3.79 26
2024 Q3 3,141,736 $8,482,377 +$68,507 $2.70 24
2024 Q2 3,127,151 $9,694,108 -$923,501 $3.10 21
2024 Q1 3,339,666 $15,162,138 -$15,603,353 $4.54 23
2023 Q4 8,791,109 $6,055,351 +$6,055,351 $0.69 3

Sponsored